OppenheimerFunds’s Ultragenyx Pharmaceutical RARE Stock Holding History

OppenheimerFunds’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-105,810	Closed	-$8.08M	–	1850
2018 Q3	$8.08M	Buy	+105,810	New	+$8.61M	0.01%	736
2017 Q4	–	Sell	-332,345	Closed	-$17.7M	–	1867
2017 Q3	$17.7M	Sell	332,345 -27,762	-8%	-$1.64M	0.02%	608
2017 Q2	$22.4M	Sell	360,107 -2,447	-0.7%	-$147K	0.03%	530
2017 Q1	$24.6M	Buy	362,554 +22,339	+7%	+$1.7M	0.03%	514
2016 Q4	$23.9M	Buy	340,215 +7,024	+2%	+$498K	0.03%	524
2016 Q3	$23.6M	Sell	333,191 -58,122	-15%	-$3.71M	0.03%	521
2016 Q2	$19.1M	Buy	391,313 +61,513	+19%	+$3.98M	0.03%	568
2016 Q1	$20.9M	Buy	329,800 +18,851	+6%	+$1.23M	0.03%	550
2015 Q4	$34.9M	Sell	310,949 -62,822	-17%	-$6.28M	0.04%	409
2015 Q3	$36M	Sell	373,771 -16,273	-4%	-$1.86M	0.05%	399
2015 Q2	$39.9M	Sell	390,044 -119,113	-23%	-$9.25M	0.05%	400
2015 Q1	$31.6M	Buy	509,157 +79,146	+18%	+$4.4M	0.04%	480
2014 Q4	$18.9M	Buy	430,011 +88,893	+26%	+$4.07M	0.02%	602
2014 Q3	$19.3M	Buy	341,118 +235,886	+224%	+$11.9M	0.02%	577
2014 Q2	$4.72M	Buy	105,232 +1,942	+2%	+$80K	0.01%	840
2014 Q1	$5.05M	Buy	+103,290	New	+$5.32M	0.01%	837

Other funds holding RARE

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

OppenheimerFunds's RARE Position: Q4 2018 in Review

OppenheimerFunds sold out of Ultragenyx Pharmaceutical (RARE) in Q4 2018, closing a stake of 105,810 shares — an estimated $8.08M sold.

OppenheimerFunds first reported a position in RARE in Q1 2014 and held it in 16 quarters. The position peaked at $39.9M in Q2 2015. 164 funds tracked by Wall St. Rank hold RARE as of Q4 2018.

OppenheimerFunds reported no remaining Ultragenyx Pharmaceutical position as of Q4 2018 after selling out during the quarter.
OppenheimerFunds sold 105,810 Ultragenyx Pharmaceutical shares in Q4 2018, an estimated $8.08M.
OppenheimerFunds first reported a position in Ultragenyx Pharmaceutical in Q1 2014 and held it in 16 quarters.
OppenheimerFunds's Ultragenyx Pharmaceutical position peaked at $39.9M in Q2 2015.
164 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q4 2018.

Based on OppenheimerFunds's 13F filing for Q4 2018, filed 11 Feb 2019.